

# Noriko Doki

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6540235/publications.pdf>

Version: 2024-02-01

61  
papers

819  
citations

759233

12  
h-index

552781

26  
g-index

62  
all docs

62  
docs citations

62  
times ranked

1178  
citing authors

#	ARTICLE	IF	CITATIONS
1	Comparing cord blood transplantation and matched related donor transplantation in non-remission acute myeloid leukemia. <i>Leukemia</i> , 2022, 36, 1132-1138.	7.2	16
2	Disease-specific impact of anti-thymocyte globulin in allogeneic hematopoietic cell transplantation: a nationwide retrospective study on behalf of the JSTCT, transplant complications working group. <i>Bone Marrow Transplantation</i> , 2022, 57, 479-486.	2.4	5
3	Letter to the Editor: Very low-dose antithymocyte globulin (thymoglobulin) is effective for steroid-refractory acute graft-versus-host disease involving the skin or gut after allogeneic hematopoietic stem cell transplantation. <i>International Journal of Hematology</i> , 2022, 115, 449.	1.6	1
4	Cyclophosphamide-induced cardiotoxicity at conditioning for allogeneic hematopoietic stem cell transplantation would occur among the patients treated with 120 mg/kg or less. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2022, , e13674.	1.1	6
5	Decision Analysis for Unrelated Bone Marrow Transplantation or Immediate Cord Blood Transplantation for Patients with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia in First Complete Remission. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 161.e1-161.e10.	1.2	1
6	The Clinical Significance of BCR-ABL1 Mutations in Patients With Philadelphia Chromosome-Positive Chronic Myeloid Leukemia Who Underwent Allogeneic Hematopoietic Cell Transplantation. <i>Transplantation and Cellular Therapy</i> , 2022, , .	1.2	0
7	The new generation tyrosine kinase inhibitor improves the survival of chronic myeloid leukemia patients after allogeneic stem cell transplantation. <i>Hematological Oncology</i> , 2022, 40, 442-456.	1.7	3
8	Essential Roles of the Transcription Factor NR4A1 in Regulatory T Cell Differentiation under the Influence of Immunosuppressants. <i>Journal of Immunology</i> , 2022, 208, 2122-2130.	0.8	6
9	Overcoming minimal residual disease using intensified conditioning with medium-dose etoposide, cyclophosphamide and total body irradiation in allogeneic stem cell transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia in adults. <i>Cytotherapy</i> , 2022, 24, 954-961.	0.7	3
10	Advantages of peripheral blood stem cells from unrelated donors versus bone marrow transplants in outcomes of adult acute myeloid leukemia patients. <i>Cytotherapy</i> , 2022, 24, 1013-1025.	0.7	3
11	Prognostic impact of TP53 mutation, monosomal karyotype, and prior myeloid disorder in nonremission acute myeloid leukemia at allo-HSCT. <i>Bone Marrow Transplantation</i> , 2021, 56, 334-346.	2.4	9
12	Changes in vaccination strategies contribute to the development of invasive pneumococcal disease in allogeneic hematopoietic stem cell transplantation recipients: a retrospective study for promoting vaccination. <i>International Journal of Hematology</i> , 2021, 114, 263-270.	1.6	1
13	Successful Cord Blood Transplantation for Idiopathic CD4 <sup>+</sup> Lymphocytopenia. <i>Acta Haematologica</i> , 2021, 144, 698-705.	1.4	1
14	Residual disease is a strong prognostic marker in patients with acute lymphoblastic leukaemia with chemotherapy-refractory or relapsed disease prior to allogeneic stem cell transplantation. <i>British Journal of Haematology</i> , 2021, 194, 403-413.	2.5	3
15	Donor-derived gene mutations in sex chromosome loss after stem cell transplantation. <i>British Journal of Haematology</i> , 2021, 195, e142-e146.	2.5	1
16	An Open-Label, Single-Arm, Multicenter Study of Ibrutinib in Japanese Patients With Steroid-dependent/Refractory Chronic Graft-Versus-Host Disease. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 867.e1-867.e9.	1.2	11
17	Nutritional risk index as a risk factor for breakthrough candidemia in allogeneic hematopoietic stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2020, 55, 661-664.	2.4	5
18	Unmanipulated haploidentical hematopoietic stem cell transplantation using very low-dose antithymocyte globulin and methylprednisolone in adults with relapsed/refractory acute leukemia. <i>Annals of Hematology</i> , 2020, 99, 147-155.	1.8	6

#	ARTICLE	IF	CITATIONS
19	Geriatric nutritional risk index as a useful prognostic factor in second allogeneic hematopoietic stem cell transplantation. <i>Annals of Hematology</i> , 2020, 99, 1655-1665.	1.8	10
20	Prebiotics protect against acute graft-versus-host disease and preserve the gut microbiota in stem cell transplantation. <i>Blood Advances</i> , 2020, 4, 4607-4617.	5.2	42
21	CT of invasive pulmonary aspergillosis (IPA) in cases with hematologic malignancy: Comparison of CT features in the group classified by the severity of neutropenia and underlying disease. <i>European Journal of Radiology</i> , 2020, 131, 109042.	2.6	1
22	Late appearance of eosinophilia in myeloid blast phase of myeloid neoplasm with rearrangement of PDGFR12. <i>Leukemia and Lymphoma</i> , 2020, 61, 1736-1739.	1.3	0
23	Outcomes and Prognostic Factors for Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia Who Underwent Allogeneic Hematopoietic Cell Transplantation: A KSGCT Multicenter Analysis. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 998-1004.	2.0	4
24	Bone turnover markers as an aid to monitor osteoporosis following allogeneic hematopoietic stem cell transplantation. <i>Annals of Hematology</i> , 2020, 99, 1873-1882.	1.8	1
25	Risk Stratification and Prognosticators of Acute Myeloid Leukemia with Myelodysplasia-Related Changes in Patients Undergoing Allogeneic Stem Cell Transplantation: A Retrospective Study of the Adult Acute Myeloid Leukemia Working Group of the Japan Society for Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1730-1743.	2.0	10
26	Geriatric nutritional risk index (GNRI) just before allogeneic hematopoietic stem cell transplantation predicts transplant outcomes in patients older than 50 years with acute myeloid leukemia in complete remission. <i>Annals of Hematology</i> , 2019, 98, 1799-1801.	1.8	9
27	Efficacy and Safety of a Weekly Cyclophosphamide-Bortezomib-Dexamethasone Regimen as Induction Therapy Prior to Autologous Stem Cell Transplantation in Japanese Patients with Newly Diagnosed Multiple Myeloma: A Phase 2 Multicenter Trial. <i>Acta Haematologica</i> , 2019, 141, 111-118.	1.4	4
28	Recipient ADAMTS13 Single-Nucleotide Polymorphism Predicts Relapse after Unrelated Bone Marrow Transplantation for Hematologic Malignancy. <i>International Journal of Molecular Sciences</i> , 2019, 20, 214.	4.1	7
29	Presacral extramedullary hematopoiesis under treatment with an erythropoietin-stimulating agent for myelodysplasia. <i>International Journal of Hematology</i> , 2019, 109, 1-2.	1.6	2
30	Reassessment of clinical implication of pretransplant surgical procedures for pulmonary invasive fungal lesions. <i>Transplant Infectious Disease</i> , 2019, 21, e13023.	1.7	1
31	Progressive hepatic cirrhosis early after allogeneic hematopoietic stem cell transplantation in a 5 patient with chronic hepatitis C infection. <i>Turkish Journal of Haematology</i> , 2019, 36, 130-133.	0.5	0
32	Clinical impact of underweight status at diagnosis on elderly patients with acute myeloid leukemia: a retrospective study of JALSG GML200. <i>Annals of Hematology</i> , 2018, 97, 1481-1483.	1.8	1
33	Underweight status at diagnosis is associated with poorer outcomes in adult patients with acute myeloid leukemia: a retrospective study of JALSG AML 201. <i>Annals of Hematology</i> , 2018, 97, 73-81.	1.8	10
34	Pyomyositis caused by <i>Streptococcus pneumoniae</i> after allogeneic hematopoietic stem cell transplantation. <i>Journal of Infection and Chemotherapy</i> , 2017, 23, 250-252.	1.7	4
35	Outcome of allogeneic hematopoietic stem cell transplantation in adult patients with acute myeloid leukemia harboring trisomy 8. <i>Annals of Hematology</i> , 2017, 96, 469-478.	1.8	6
36	The recipient CCR5 variation predicts survival outcomes after bone marrow transplantation. <i>Transplant Immunology</i> , 2017, 42, 34-39.	1.2	5

#	ARTICLE	IF	CITATIONS
37	Erythrocytosis after allogeneic hematopoietic stem cell transplantation. <i>Clinical Transplantation</i> , 2017, 31, e12918.	1.6	0
38	Central Nervous System Involvement at the Time of Allogeneic Hematopoietic Stem Cell Transplantation Is Associated with a Poor Outcome in Patients with Acute Myeloid Leukemia. <i>Pathology and Oncology Research</i> , 2017, 23, 433-437.	1.9	8
39	Clinical impact of pre-transplant gut microbial diversity on outcomes of allogeneic hematopoietic stem cell transplantation. <i>Annals of Hematology</i> , 2017, 96, 1517-1523.	1.8	48
40	Sudden blindness as an initial manifestation of localized fusariosis in ethmoid sinus and optic nerve. <i>Annals of Hematology</i> , 2017, 96, 1771-1772.	1.8	0
41	Mycophenolate mofetil is effective only for involved skin in the treatment for steroid-refractory acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. <i>Annals of Hematology</i> , 2017, 96, 319-321.	1.8	3
42	Impact of total body irradiation on successful neutrophil engraftment in unrelated bone marrow or cord blood transplantation. <i>American Journal of Hematology</i> , 2017, 92, 171-178.	4.1	38
43	Disseminated nocardiosis after unrelated bone marrow transplantation. <i>Transplant Infectious Disease</i> , 2016, 18, 942-945.	1.7	8
44	Toll - like receptor 1 variation increases the risk of transplant-related mortality in hematologic malignancies. <i>Transplant Immunology</i> , 2016, 38, 60-66.	1.2	3
45	The clinical features of fatal cyclophosphamide-induced cardiotoxicity in a conditioning regimen for allogeneic hematopoietic stem cell transplantation (allo-HSCT). <i>Annals of Hematology</i> , 2016, 95, 1145-1150.	1.8	41
46	Optic neuritis as an initial manifestation of human herpesvirus 6 reactivation after unrelated bone marrow transplantation. <i>British Journal of Haematology</i> , 2016, 172, 654-654.	2.5	6
47	Allogeneic hematopoietic stem cell transplant overcomes poor prognosis of acute myeloid leukemia with myelodysplasia-related changes. <i>Leukemia and Lymphoma</i> , 2016, 57, 76-80.	1.3	19
48	CD25 expression on residual leukemic blasts at the time of allogeneic hematopoietic stem cell transplant predicts relapse in patients with acute myeloid leukemia without complete remission. <i>Leukemia and Lymphoma</i> , 2016, 57, 1375-1381.	1.3	10
49	Biological significance of HLA locus matching in unrelated donor bone marrow transplantation. <i>Blood</i> , 2015, 125, 1189-1197.	1.4	185
50	A donor thrombomodulin gene variation predicts graft-versus-host disease development and mortality after bone marrow transplantation. <i>International Journal of Hematology</i> , 2015, 102, 460-470.	1.6	8
51	Toxic encephalopathy after exposure to azacitidine. <i>Leukemia and Lymphoma</i> , 2015, 56, 1538-1539.	1.3	2
52	Clinical impact of hematogones on outcomes of allogeneic hematopoietic stem cell transplantation. <i>Annals of Hematology</i> , 2015, 94, 2055-2060.	1.8	11
53	Age influences post-graft-versus-host disease non-relapse mortality in adults with acute graft-versus-host disease of varying severity following allogeneic hematopoietic cell transplant. <i>Leukemia and Lymphoma</i> , 2015, 56, 2392-2397.	1.3	6
54	Post-transplant maintenance therapy with azacitidine and gemtuzumab ozogamicin for high-risk acute myeloid leukaemia. <i>British Journal of Haematology</i> , 2015, 169, 756-759.	2.5	48

#	ARTICLE	IF	CITATIONS
55	Clinical impact of CD25 expression on outcomes of allogeneic hematopoietic stem cell transplant for cytogenetically intermediate-risk acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2015, 56, 1874-1877.	1.3	3
56	Development of aggressive T-cell leukemia at 1 month after the diagnosis of hypereosinophilic syndrome. <i>Leukemia and Lymphoma</i> , 2014, 55, 2402-2404.	1.3	2
57	Clinical Outcome of Hematopoietic Stem Cell Transplantation for Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph + ALL): Experience From a Single Institution. <i>Pathology and Oncology Research</i> , 2014, 20, 61-66.	1.9	8
58	Outcome of Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia Patients with Central Nervous System Involvement. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 2029-2033.	2.0	34
59	Clinical Factors Predicting the Response of Acute Graft-versus-Host Disease to Corticosteroid Therapy: An Analysis from the GVHD Working Group of the Japan Society for Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 1183-1189.	2.0	63
60	Risk Assessment for Acute Kidney Injury after Allogeneic Hematopoietic Stem Cell Transplantation Based on Acute Kidney Injury Network Criteria. <i>Internal Medicine</i> , 2012, 51, 2105-2110.	0.7	47
61	A high risk of life-threatening infectious complications in mycophenolate mofetil treatment for acute or chronic graft-versus-host disease. <i>International Journal of Hematology</i> , 2010, 91, 464-470.	1.6	20